Sanofi's Top-Selling Drug Just Snagged Another Approval From the FDA

Sanofi's Top-Selling Drug Just Snagged Another Approval From the FDA

Source: 
Motley Fool
snippet: 
  • Dupixent now has access to a market of tens of thousands of patients.
  • It could bring nearly $900 million in annual sales for Sanofi and Regeneron to split.
  • Sanofi looks like a reasonably priced stock for its growth prospects.